Neurogene (NASDAQ:NGNE) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Neurogene (NASDAQ:NGNE) in a research report report published on Tuesday,Benzinga reports. The firm currently has a $55.00 target price on the stock. HC Wainwright also issued estimates for Neurogene’s Q4 2024 earnings at ($1.05) EPS, FY2024 earnings at ($4.34) EPS, Q1 2025 earnings at ($0.77) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.83) EPS and FY2025 earnings at ($3.19) EPS.

Other equities analysts have also issued research reports about the stock. Stifel Nicolaus boosted their price objective on shares of Neurogene from $44.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. Leerink Partners raised their price objective on Neurogene from $45.00 to $72.00 and gave the stock an “outperform” rating in a report on Tuesday, November 12th. BMO Capital Markets dropped their target price on Neurogene from $65.00 to $60.00 and set an “outperform” rating for the company in a research note on Tuesday, November 12th. Finally, Robert W. Baird upped their price objective on shares of Neurogene from $54.00 to $72.00 and gave the company an “outperform” rating in a research note on Tuesday, November 12th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Neurogene currently has a consensus rating of “Buy” and a consensus price target of $60.83.

Neurogene Stock Performance

Shares of NASDAQ:NGNE opened at $20.30 on Tuesday. The stock’s fifty day simple moving average is $44.97 and its 200-day simple moving average is $39.53. Neurogene has a 52-week low of $12.49 and a 52-week high of $74.49.

Institutional Trading of Neurogene

A number of institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new stake in shares of Neurogene in the first quarter worth about $120,000. Vanguard Group Inc. boosted its stake in shares of Neurogene by 906.5% in the first quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock valued at $25,831,000 after purchasing an additional 457,062 shares during the period. Baker BROS. Advisors LP boosted its stake in shares of Neurogene by 0.6% in the first quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company’s stock valued at $23,211,000 after purchasing an additional 2,499 shares during the period. Bank of New York Mellon Corp purchased a new stake in Neurogene during the 2nd quarter worth $1,107,000. Finally, Rhumbline Advisers acquired a new position in Neurogene in the 2nd quarter worth $491,000. 52.37% of the stock is owned by hedge funds and other institutional investors.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.